NEW YORK, Aug. 17, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocular Therapeutix, Inc. (NASDAQ:OCUL) who purchased shares between March 10, 2016 and July 11, 2017. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Shareholders have until September 5, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/ocular-therapeutix-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 



